Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals discovers and develops medicines in cellular metabolism. Lead product is PYRUKYND (mitapivat) for hemolytic anemias. Developing AG-946 for lower-risk myelodysplastic syndrome and hemolytic anemias, and AG-181 for phenylketonuria. Also developing siRNA for polycythemia vera, a rare blood disorder. Company was incorporated in 2007. Headquartered in Cambridge, Massachusetts.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

39.9 USD

Potential

-100%

Strengths

Current Price to Earnings Ratio (3.40) is lower than the sector mean (91.15).
Price to book ratio (1.49) is lower than the sector mean (24.44).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	3.4
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.0

Agios Pharmaceuticals, Inc.

Overview

Strengths

Weaknesses

Key Financial Data